Development of novel therapies for Huntington's disease: hope and challenge

被引：0
|
作者：
Zheng-hong Qin
Jin Wang
Zhen-lun Gu
机构：
[1] Soochow University School of Medicine,Department of Pharmacology
[2] Laboratory of Cellular Neurobiology,undefined
[3] Massachusetts General Hospital and Harvard Medical School,undefined
[4] Molecular Neurogenetics Unit,undefined
[5] Center for Human Genetics Research,undefined
[6] Massachusetts General Hospital and Harvard Medical School,undefined
来源：
Acta Pharmacologica Sinica | 2005年 / 26卷
关键词：
Huntington disease; huntingtin; aggregates; caspases; nerve growth factors; cell transplantation; coenzyme Q10;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Huntington's disease (HD) is an autosomal dominant neurological disease. It is a fatal neurological disorder affecting 5–10 out of 10 000 people. While there are intensive research efforts focusing on uncovering molecular mechanisms of the pathogenesis of HD, a number of studies have begun to look for effective therapies for HD. There is a large body of encouraging news on novel therapeutic developments. The present paper reviews drugs used for symptomatic treatment of HD and experimental therapies targeting HD molecular pathology.
引用
收藏
页码：129 / 142
页数：13
相关论文
共 50 条
12345